Want to see IRIX full AI Analyst Report?
IRIX Stock Chart & Stats
$0.72
>-$0.01(-0.56%)
At close: 4:00 PM EDT
$0.72
>-$0.01(-0.56%)
Day’s Range― - ―
52-Week Range$0.61 - $1.65
Previous CloseN/A
Volume11.00K
Average Volume (3M)751.86K
Market Cap
$13.26M
Enterprise Value$25.02M
Total Cash (Recent Filing)$4.68M
Total Debt (Recent Filing)$4.01M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Nov 17, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding17,564,913
10 Day Avg. Volume2,146,067
30 Day Avg. Volume751,862
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)4.09
Price to Sales (P/S)0.38
P/FCF Ratio-8.91
Enterprise Value/Market Cap1.89
Enterprise Value/Revenue0.49
Enterprise Value/Gross Profit1.34
Enterprise Value/Ebitda-14.66
Forecast
1Y Price Target
$2.75Price Target Upside281.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$53.00M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueRecurring probes, fibers, service, and maintenance revenue gives Iridex a more durable foundation than capital-equipment sales alone. As procedures and installed systems expand, these activities can support repeat purchasing, improve revenue visibility, and deepen customer relationships over the next several quarters.
Glaucoma Product MomentumStrong Cyclo G6 utilization and revenue growth indicate meaningful traction in glaucoma, partially offsetting weakness in retina. Continued probe adoption can expand recurring consumable revenue, support the installed base, and improve the business mix if management sustains this momentum.
Low Debt BurdenVery low debt reduces interest burden and near-term refinancing pressure, giving Iridex greater flexibility while it works toward profitability. Although the equity cushion is limited, the current capital structure is less levered than in prior years and therefore less exposed to debt-driven financial stress.
Bears Say
Persistent Losses And Cash BurnNegative operating and free cash flow show that Iridex has not yet converted its business into consistent self-funded growth. Continued losses can consume the company’s limited cash resources, restrict investment in commercialization, and increase dependence on financing or operational improvements.
Weak Revenue And ProfitabilityFlat-to-declining revenue combined with negative operating and net margins indicates that Iridex has not established durable earnings power. Even though performance improved from the 2023–2024 trough, inconsistent demand and ongoing losses may limit reinvestment and delay sustainable profitability.
Nasdaq Listing Compliance RiskThe minimum-bid deficiency creates an ongoing corporate risk that could require a reverse split or other corrective action if compliance is not restored. Potential delisting would reduce market visibility and liquidity, complicating access to investors while management is addressing operating challenges.
Iridex News
IRIX FAQ
What was Iridex Corp’s price range in the past 12 months?
Iridex Corp lowest stock price was $0.61 and its highest was $1.65 in the past 12 months.
What is Iridex Corp’s market cap?
Iridex Corp’s market cap is $13.26M.
When is Iridex Corp’s upcoming earnings report date?
Iridex Corp’s upcoming earnings report date is Nov 17, 2026 which is in 26 days.
How were Iridex Corp’s earnings last quarter?
Iridex Corp released its earnings results on Aug 18, 2026. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.01 by -$0.06.
Is Iridex Corp overvalued?
According to Wall Street analysts Iridex Corp’s price is currently Undervalued.
Does Iridex Corp pay dividends?
Iridex Corp does not currently pay dividends.
What is Iridex Corp’s EPS estimate?
Iridex Corp’s EPS estimate is -0.04.
How many shares outstanding does Iridex Corp have?
Iridex Corp has 17,564,913 shares outstanding.
What happened to Iridex Corp’s price movement after its last earnings report?
Iridex Corp reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.01. Following the earnings report the stock price went down -15.914%.
Which hedge fund is a major shareholder of Iridex Corp?
Currently, no hedge funds are holding shares in IRIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Iridex Corp
IRIDEX Corporation is a medical technology firm specializing in ophthalmology. They develop and supply advanced therapeutic laser systems, various delivery instruments, and essential consumable tools designed to address vision-threatening ocular conditions. Their product portfolio includes several laser consoles, each tailored for specific eye conditions. The Cyclo G6 system is specifically engineered for glaucoma treatment. For ailments like diabetic macular edema and other retinal pathologies, IRIDEX provides the IQ 532 and IQ 577 laser photocoagulation systems. Furthermore, the OcuLight series, encompassing models such as TX, SL, SLx, GL, and GLx, offers solutions for managing severe retinal issues like proliferative diabetic retinopathy, macular holes, and retinal tears or detachments. Beyond laser consoles, the company also manufactures specialized delivery instruments. These include the TxCell scanning laser delivery system, which empowers clinicians with multi-spot pattern scanning capabilities. A unique slit lamp adapter enables practitioners to integrate standard slit lamps into their diagnostic and therapeutic workflows. Additionally, a laser indirect ophthalmoscope is available for interventions targeting peripheral retinal disorders. IRIDEX's offerings extend to various probes. The MicroPulse P3 Probe, when coupled with the Cyclo G6 laser system, facilitates MicroPulse transscleral laser therapy. For managing uncontrolled glaucoma, the G-Probe is employed, while both the G-Probe and G-Probe Illuminate are utilized in procedures addressing refractory glaucoma. The EndoProbe product line supports a range of vitrectomy procedures. Their diverse client base spans ophthalmology professionals, academic and research hospitals, government healthcare facilities, specialized surgical centers, general hospitals, veterinary clinics, and private medical practices. Product distribution is handled via an internal and independent sales network across the United States, supplemented by independent distributors for its international markets. Originally incorporated in 1989 as IRIS Medical Instruments, Inc., the company adopted the name IRIDEX Corporation in November 1995. Its corporate headquarters are situated in Mountain View, California.
IRIX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: clear operational progress and cost discipline produced positive operating cash flow and meaningful glaucoma momentum (notably probe volumes and G6 revenue growth), and management reaffirmed full-year guidance and laid out plans to improve margins via a headquarters relocation and contract manufacturing. Offsetting these positives were a year-over-year revenue decline driven by a pronounced drop in retina sales, a wider net loss and a swing to negative adjusted EBITDA, fewer system placements, and temporary working capital strain tied to inventory buildup and regulatory transitions. Management expects these issues to normalize over H2 and into 2027, but near-term volatility remains.View all IRIX earnings summariesIRIX Stock 12 Month Forecast
Average Price Target
$2.75
▲(281.94% Upside)
Technical Analysis
Sintx Technologies
―
PAVmed
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Envoy Medical
―
Ownership Overview
21.15% Insiders
3.57% Mutual Funds
0.95% Other Institutional Investors
71.40% Public Companies and
Individual Investors